IL7 and COVID-19: Our results support a proposal by Bermejo-Martin et al. [34]: novel drugs targeting lymphocyte proliferation or apoptosis (IL-7 or PD-1/PD-L1 inhibitors), that having action of mechanism associated with restore lymphocyte, could be worthy for patients suffering from a severe course of COVID-19.